Statement Of Comprehensive Income [Abstract]

Sopharma AD - Filing #6022421

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Statement of comprehensive income [abstract]
Profit (loss)	99 874 BGN	3 897 BGN	95 977 BGN	95 977 BGN	—	—	—	71 121 BGN	—	76 333 BGN	—	71 121 BGN	5 212 BGN	—
Other comprehensive income [abstract]
Components of other comprehensive income that will be reclassified to profit or loss, before tax [abstract]
Exchange differences on translation [abstract]
Gains (losses) on exchange differences on translation of foreign operations, before tax	1 302 BGN	—	—	—	—	—	—	—	—	4 637 BGN	—	—	—	—
Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, before tax	4 893 BGN	—	—	—	—	—	—	—	—	790,000 BGN	—	—	—	—
Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss [abstract]
Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss	3,000 BGN	—	—	—	—	—	—	—	—	99,000 BGN	—	—	—	—
Other comprehensive income	3 915 BGN	84,000 BGN	1 388 BGN	3 999 BGN	1 766 BGN	30,000 BGN	3 591 BGN	6 011 BGN	892,000 BGN	5 868 BGN	1 047 BGN	1 355 BGN	143,000 BGN	5 427 BGN
Comprehensive income	103 789 BGN	3 813 BGN	94 589 BGN	99 976 BGN	1 766 BGN	30,000 BGN	3 591 BGN	65 110 BGN	892,000 BGN	70 465 BGN	1 047 BGN	72 476 BGN	5 355 BGN	5 427 BGN
Comprehensive income attributable to [abstract]
Comprehensive income, attributable to owners of parent	99 976 BGN	—	—	—	—	—	—	—	—	65 110 BGN	—	—	—	—
Comprehensive income, attributable to non-controlling interests	3 813 BGN	—	—	—	—	—	—	—	—	5 355 BGN	—	—	—	—